Price (delayed)
$6.575
Market cap
$358.56M
P/E Ratio
25.29
Dividend/share
N/A
EPS
$0.26
Enterprise value
$282.43M
Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation
There are no recent dividends present for VYGR.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.